For CD Patients, Ciprofloxacin May Not Be Best for Intra-Abdominal Abscess

the MPR take:

Ciprofloxacin, a quinolone antibiotic, may be the most frequently used drug for the treatment of Crohn’s disease (CD); however, what researchers discovered from isolating abscesses in CD patients may put into question whether the drug should be considered first-line treatment. In a study published in the Journal of Clinical Gastroenterology, researchers looked at the clinical outcomes of 78 CD patients who underwent percutaneous drainage after being diagnosed with intra-abdominal abscesses. In patients where gram-negative aerobes were discovered in the abscess, more than 2/3 of the bacteria were resistant to ciprofloxacin. Clinicians treating CD patients with intra-abdominal abscesses should consider this high rate of ciprofloxacin resistance when choosing appropriate therapy for their patients.

Background: Ciprofloxacin is the antibiotic most frequently used in the treatment of Crohn's disease (CD). We attempted to identify the microorganisms present in CD-related intra-abdominal abscesses, their ciprofloxacin resistance patterns, and the clinical impact. Methods: Microorganisms, their ciprofloxacin resistance, and clinical outcomes were retrospectively analyzed in 78 CD patients with intra-abdominal abscesses, who underwent percutaneous drainage between March 1991 and November 2011.